Beam Therapeutics (BEAM) Leases (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Leases data on file, last reported at $98.1 million in Q1 2026.

• Quarterly Leases fell 3.98% year-over-year to $98.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.1 million (down 3.98% YoY) and the FY2025 annual result came in at $100.7 million, down 3.99% from the prior year.
• Leases fell to $98.1 million in Q1 2026 per BEAM's latest filing, from $100.7 million in the prior quarter.
• Across five years, Leases topped out at $118.5 million in Q4 2022 and bottomed at $13.6 million in Q2 2022.
• The 5-year median for Leases is $105.5 million (2022), against an average of $101.9 million.
• The widest annual swing landed in 2022, when Leases tumbled 87.09%; it then soared 738.79% in 2023.
• Tracing BEAM's Leases over 5 years: stood at $118.5 million in 2022, then retreated by 4.78% to $112.8 million in 2023, then dropped by 7.07% to $104.9 million in 2024, then dropped by 3.99% to $100.7 million in 2025, then slipped by 2.51% to $98.1 million in 2026.
• Per Business Quant, the three latest BEAM Leases figures stand at $98.1 million (Q1 2026), $100.7 million (Q4 2025), and $97.0 million (Q3 2025).

Peer Comparison